about
Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in developmentThe novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H2O2-induced cell injury via NF-E2-related factor 2 (Nrf2) activationPeptide redesign for inhibition of the complement system: Targeting age-related macular degeneration.PTEN Reduced UVB-Mediated Apoptosis in Retinal Pigment Epithelium Cells.Recent developments in ocular drug delivery.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Current choice of treatments for neovascular AMD.
@en
type
label
Current choice of treatments for neovascular AMD.
@en
prefLabel
Current choice of treatments for neovascular AMD.
@en
P2860
P1476
Current choice of treatments for neovascular AMD.
@en
P2093
Gennady Landa
P2860
P304
P356
10.1586/17512433.2015.990379
P407
P577
2015-01-01T00:00:00Z